Skip to content

Evaluation of the Efficacy and Safety of Oliceridine Combined with Propofol for Anesthesia in Elderly Patients Undergoing Endoscopic Mucosal Resection of Colorectal Polyps

Evaluation of the Efficacy and Safety of Oliceridine Combined with Propofol for Anesthesia in Elderly Patients Undergoing Endoscopic Mucosal Resection of Colorectal Polyps

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106872
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Polyps

Interventions

ED50 group:The ED50 was determined using Dixon’s up-and-down method. An effective anesthetic response was defined as a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score = 1 and absen
Oliceridine group:The ED95 of oliceridine determined in the first phase was administered via slow intravenous injection. Simultaneously, propofol was infused using target-controlled infusion (TCI) at
Sufentanil group:According to the literature, the sufentanil dose was calculated based on an equivalent ratio of 200:1 to oliceridine (ED95/200) and administered via slow intravenous injection. Simult

Sponsors

Jurong People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged >=65 years with colorectal polyps scheduled for elective endoscopic mucosal resection (EMR); 2. ASA physical status classification I–III; 3.Clear consciousness before surgery, able to communicate normally, understand the study content, and provide written informed consent; 4. Body Mass Index (BMI) between 18 and 30 kg/m^2; 5. No planned combined surgery, EMR procedure performed as a standalone operation.

Exclusion criteria

Exclusion criteria: 1. Severe dysfunction of the liver, kidneys, heart, or brain (e.g., Child-Pugh class C, eGFR < 30 ml/min, NYHA class IV cardiac function, recent history of stroke, etc.); 2. Known or suspected allergy to oliceridine, propofol, sufentanil, or related drugs; 4. Decompensated respiratory diseases (e.g., severe COPD, untreated moderate-to-severe OSAHS); 5.Active bleeding, coagulopathy, or ongoing anticoagulant therapy that cannot be discontinued prior to surgery; 6.Preoperative psychiatric disorders, cognitive impairment, or altered consciousness; 7. Prior participation in similar clinical studies involving anesthetic agents.

Design outcomes

Primary

MeasureTime frame
Oliceridine dosage;Incidence of respiratory depression;

Secondary

MeasureTime frame
Hemodynamic changes;Waking time;The incidence of postoperative nausea and vomiting;Patient satisfaction;QoR-15;

Countries

China

Contacts

Public ContactLiu Ying

Jurong People's Hospital

1398347480@qq.com+86 159 5297 2676

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026